Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (96)
June 23, 2008
- Maurer's Healthcare Insight (95)
May 19, 2008
- Maurer's Healthcare Insight (94)
March 10, 2008
- Maurer's Healthcare Insight (93)
February 18, 2008
- Maurer's Healthcare Insight (92)
January 21, 2008
- Maurer's Healthcare Insight (91)
December 24, 2007
- Maurer's Healthcare Insight (90)
November 5, 2007
- Maurer's Healthcare Insight (89)
October 8, 2007
- Maurer's Healthcare Insight (88)
August 6, 2007
- Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
- Maurer's Healthcare Insight (86)
May 28, 2007
- Maurer's Healthcare Insight (85)
April 16, 2007
- Maurer's Healthcare Insight (84)
March 26, 2007
- Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
- Maurer's Healthcare Insight (83)
February 19, 2007
- 2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
- Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer
December 18, 2006
- Maurer's Healthcare Insight (81)
November 20, 2006
- Maurer's Healthcare Insight (80)
October 23, 2006
- Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…